Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Germ Cell Tumor: early-phase trial registry
9 of 20 indexed Germ Cell Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 9 currently recruiting · #848 of 28,707 conditions by registered trial count
Germ Cell Tumor: 20 US clinical trials tracked, 9 recruiting.
Germ Cell Tumor is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 4 of these trials.
Enrollment posture brief
Registry condition germ-cell-tumor
OPEN 9 | RECR 45% | LATE 3 | EARLY 12 | RANK #848 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Invasive Breast Cancer (45% recruiting · 20 trials)
Germ Cell Tumor lists 9 open slots (45% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Germ Cell Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Germ Cell Tumor is recruiting above its size-band peers.
9 of 20 indexed trials (45%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Germ Cell Tumor research.
Seattle Children's Hospital accounts for 4 of 20 trials (20%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Germ Cell Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 20 trials that report a genuine target (sentinel values excluded). 13 of those (65%) plan for fewer than 100 participants.
-
Germ Cell Tumor research is mostly interventional.
16 interventional and 4 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Children's Oncology Group
NCT03067181
Molecular Epidemiology of Pediatric Germ Cell Tumors
Children's Oncology Group
NCT05564026
Germ Cell Tumor and Testicular Tumor DNA Registry
Memorial Sloan Kettering Cancer Center
NCT02099734
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
University of Sydney
NCT02582697
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor
NCT06276491
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
NCT04185038
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Nabil Adra
NCT04804007
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Indiana University
NCT06937866
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT06866964
A Study of miRNA 371 in Patients With Germ Cell Tumors
SWOG Cancer Research Network
NCT04435756
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Alliance for Clinical Trials in Oncology
NCT02375204
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Jennifer King
NCT04876456
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
Massachusetts General Hospital
NCT01049230
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
NCT03158064
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Seattle Children's Hospital
NCT03500991
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Nasser Hanna
NCT02429466
Role of Axumin PET Scan in Germ Cell Tumor
University of Texas Southwestern Medical Center
NCT03426865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Germ Cell Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Germ Cell Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Germ Cell Tumor page
20 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Germ Cell Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seattle Children's Hospital sponsors the most Germ Cell Tumor trials on record, review their full trial history before evaluating a specific study. See Seattle Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Germ Cell Tumor condition card totals 20 registered trials; most-linked intervention Etoposide; top US site state Indiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.